<?xml version="1.0" encoding="UTF-8"?>
<p>Clinical trials of therapeutic drugs involving hundreds of COVID-19 patients were ongoing by early February [
 <xref rid="ppat.1008902.ref050" ref-type="bibr">50</xref>]. During March and April, numerous compounds were identified that either have direct action on SARS-CoV-2 in vitro [
 <xref rid="ppat.1008902.ref045" ref-type="bibr">45</xref>,
 <xref rid="ppat.1008902.ref051" ref-type="bibr">51</xref>â€“
 <xref rid="ppat.1008902.ref053" ref-type="bibr">53</xref>] or may have indirect action via host proteins [
 <xref rid="ppat.1008902.ref039" ref-type="bibr">39</xref>,
 <xref rid="ppat.1008902.ref054" ref-type="bibr">54</xref>], paving the way for in vivo efficacy trials (
 <xref ref-type="fig" rid="ppat.1008902.g001">Fig 1</xref>). Furthermore, on the basis of 2 clinical trials, the FDA granted an EUA of remdesivir for COVID-19 treatment on May 1, 2020 [
 <xref rid="ppat.1008902.ref055" ref-type="bibr">55</xref>]. This was the first direct antiviral approval, just over 4 months into the outbreak.
</p>
